Norfloxacin EP Impurity I - Request Quote
Norfloxacin EP Impurity I
| SZ CAT No: | SZ-N014022 |
| CAS No | NA |
| Mol.F. | C19H22ClN3O5 |
| Mol.Wt. | 407.9 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Norfloxacin EP Impurity I is chemically 7-Chloro-6-[4-(ethoxycarbonyl)piperazin-1-yl]-1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (as per EP). Norfloxacin EP Impurity I is supplied with detailed characterization data compliant with regulatory guideline. Norfloxacin EP Impurity I can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Norfloxacin.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
buy high quality Norfloxacin EP Impurity I
Purchase Norfloxacin EP Impurity I
Norfloxacin EP Impurity I suppliers
Norfloxacin EP Impurity I manufacturers
Norfloxacin EP Impurity I price
Order Norfloxacin EP Impurity I
Enquire Norfloxacin EP Impurity I
Norfloxacin EP Impurity I cost
Norfloxacin EP Impurity I Supplier
Norfloxacin EP Impurity I Distributor
Norfloxacin EP Impurity I for Method Validation
Norfloxacin Reference Standard
Norfloxacin EP Impurity I for ANDA Filing
Norfloxacin EP Impurity I for Forced Degradation Studies
Norfloxacin EP Impurity I Identification Standards
Norfloxacin EP Impurity I for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


